The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index; 19 of the 54 sources its claims cite were checked for support.
Fear of cancer recurrence in breast cancer survivors carrying a BRCA1 or 2 genetic mutation : a cross-sectional study
Open accessAbstract
Background: Fear of cancer recurrence (FCR) affects virtually all patients who have been treated for cancer, to varying degrees. Breast cancer survivors who carry a BRCA1 or BRCA2 gene mutation are at high risk of cancer recurrence. No study has yet assessed FCR specifically in this population. Objectives: This cross-sectional study, conducted in women who were treated for breast cancer and carrying a BRCA1/2 mutation, aimed to: (1) assess the mean level of FCR and estimate the proportion of patients with clinical levels of FCR; (2) examine the relationships between FCR and selected psychological variables (e.g., avoidance, intolerance to uncertainty) and quality of life; (3) explore whether FCR levels vary as a function of the past preventive treatment received; and (4) to assess the associations between FCR and the presence of decisional conflict or regret regarding the various preventive options. Method: Participants were recruited through an e-mail sent to an oncogenetic network mailing list (Réseau ROSE). Participants were asked to complete a battery of questionnaires online assessing FCR and other psychological and quality of life variables. Results: A total of 89 women completed the survey. Most participants had undergone a preventive mastectomy (62.9%) and a preventive salpingo-oophorectomy (75.3%) at the time of the study. The mean Fear of Cancer Recurrence Inventory-severity score was 16.8, which exceeds the clinical cut-off score of 13, and 70.8% of the participants showed a clinical level of FCR. FCR was significantly associated with higher levels of anxiety and depression, and higher avoidance and intolerance of uncertainty, but not with quality of life. No significant difference was observed on the total FCR score between women who had received preventive surgery (mastectomy and/or salpingo-oophorectomy) and those considering it, and those not considering it. The association was significant between higher FRC scores and greater decisional conflicts and regrets about choosing to undergo preventive surgery. Conclusion: These data suggest that FCR is a significant problem for breast cancer survivors carrying a BRCA1/2 genetic mutation, even after undergoing a prophylactic surgery. This highlights the importance of providing these women with specific psychological intervention focusing on FCR. © The Author(s) 2024.
Overview
CoChat Summary
## TL;DR
This cross-sectional study found that fear of cancer recurrence (FCR) was highly prevalent among 89 breast cancer survivors carrying a BRCA1/2 mutation, even though most had already undergone preventive surgery. Higher FCR was linked to anxiety, depression, intolerance of uncertainty, avoidance, and decisional conflict/regret, but not to quality of life.
## Key findings
- Among 89 participants, the mean Fear of Cancer Recurrence Inventory-severity score was 16.8, above the clinical cut-off of 13, and 70.8% showed a clinical level of FCR.
- FCR was significantly associated with higher anxiety, depression, avoidance, and intolerance of uncertainty; correlations with the total FCRI score included anxiety (r = 0.694), depression (r = 0.423), and intolerance of uncertainty (r = 0.430).
- FCR was not significantly associated with quality of life (r = -0.171, p = 0.128).
- Past preventive treatment was not significantly related to FCR: no between-group differences were found across women who had mastectomy only, salpingo-oophorectomy only, both procedures, or no procedure; FCR was also not significantly related to time since the most recent preventive surgery.
- Higher FCR was significantly associated with greater decisional conflict and decisional regret; for the total FCRI score, r = 0.235 with decisional conflict and r = 0.337 with regret.
## Methods
- Cross-sectional survey of women aged 18–80 treated for non-metastatic breast or ovarian cancer, carrying a BRCA1 or BRCA2 mutation, and able to read French; women on active cancer treatment other than adjuvant hormone therapy were excluded.
- Recruitment was through an email announcement sent to the ROSE oncogenetic network mailing list in Quebec, Canada, between October 9, 2020 and May 10, 2021; 89 women completed the survey, and all available data were used in analyses.
- Participants completed online questionnaires measuring FCR, anxiety and depression (HADS), intolerance of uncertainty (IUS), trauma-related symptoms (IES), quality of life (QLQ-C30), decisional conflict (DCS), and decisional regret (DRS); analyses included descriptive statistics, multivariable linear models, correlations, and ANOVAs.
## Limitations
- The paper states that it used a convenience sample because there was no population-based registry, so selection bias is possible and generalizability to the full population is uncertain.
- The study was cross-sectional, so it could not assess change over time or make causal inferences.
- The paper states that statistical power was limited for some comparative analyses because of sample size; additionally, recruitment occurred during the second and third COVID-19 waves, which may have temporarily increased anxiety about medical care.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
14 Valid · 0 Not valid · 14 Not checked · 60 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In addition to having an increased risk of developing a first breast cancer, women with a BRCA1/2 genetic mutation and who have been treated for breast cancer are also at an increased risk of having a local recurrence or a second primary cancer.”
§ Fear of cancer recurrence in breast cancer survivors carrying a BRCA1 or 2 genetic mutation : a cross-sectional study > Introduction
What the sources say
- Supportedcites [13] Nilsson MP, Hartman L, Kristoffersson U, Johannsson OT, Borg Å, Henriksson K, et al. High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer. Breast Cancer Res Treat. 2014;147(3):571–8. source
The Discussion reports that BRCA1/2 carriers had a substantially higher risk of local recurrence after breast-conserving therapy than after mastectomy, and more than twice the risk seen after breast-conserving therapy in the general population. The Introduction describes a very high risk of contralateral breast cancer after a carrier’s first cancer, while the Discussion says many local recurrences are probably new primary cancers. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [14] Bordeleau L, Panchal S, Goodwin P. Prognosis of BRCA-associated breast cancer: a summary of evidence. Breast Cancer Res Treat. 2010;119:13–24. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“two systematic reviews found higher levels of distress, anxiety, and depression in carriers compared to non-carriers following the announcement of the genetic test result [17, 18].”
§ Fear of cancer recurrence in breast cancer survivors carrying a BRCA1 or 2 genetic mutation : a cross-sectional study > Introduction
What the sources say
- Not checked — no full text of the sourcecites [17] Lombardi L, Bramanti SM, Babore A, Stuppia L, Trumello C, Antonucci I, et al. Psychological aspects, risk and protective factors related to BRCA genetic testing: a review of the literature. Support Care Cancer. 2019;27(10):3647–56. source
- Partly supportedcites [18] Ringwald J, Wochnowski C, Bosse K, Giel KE, Schäffeler N, Zipfel S, et al. Psychological distress, anxiety, and depression of cancer-affected BRCA1/2 mutation carriers: a systematic review. J Genet Couns. 2016;25(5):880–91. sourceExperimental — accuracy not yet measured
The Distress section (page unavailable) reports higher distress in mutation carriers than non-carriers during the first six months after testing. The Anxiety and Depression section (page unavailable) reports higher scores in some studies, but the findings are inconsistent; the review does not establish that carriers generally have higher levels of all three outcomes than non-carriers. Its focus is also cancer-affected carriers, rather than all BRCA1/2 carriers. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Since the risk of recurrence is higher in carriers of the BRCA1 than BRCA2 gene mutation [33]”
§ Fear of cancer recurrence in breast cancer survivors carrying a BRCA1 or 2 genetic mutation : a cross-sectional study > Introduction
What the sources say
- Partly supportedcites [33] van den Broek AJ, van ‘t Veer LJ, Hooning MJ, Cornelissen S, Broeks A, Rutgers EJ, et al. Impact of age at primary breast Cancer on contralateral breast Cancer risk in BRCA1/2 mutation carriers. J Clin Oncol. 2016;34(5):409–18. sourceExperimental — accuracy not yet measured
The Discussion reports a higher 10-year risk of contralateral breast cancer in BRCA1 carriers (21.1%) than in BRCA2 carriers (10.8%). But the Statistical Analysis section defines that outcome as a second primary cancer and treats local and regional recurrences separately. The paper therefore supports the comparison for contralateral breast cancer, not for recurrence. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A systematic review by Crist and Grunfeld [5] revealed that younger age was associated in almost every study with higher FCR for different cancer types, including breast cancer [53–55].”
§ Fear of cancer recurrence in breast cancer survivors carrying a BRCA1 or 2 genetic mutation : a cross-sectional study > Discussion
What the sources say
- Not checked yetcites Crist and Grunfeld [5] Crist JV, Grunfeld EA. Factors reported to influence fear of recurrence in cancer patients: a systematic review. Psycho-oncology. 2013;22(5):978–86. source
Checked before — its earlier verdict is held back until a new check runs.
- Not checked — no full text of the sourcecites [53] Koch L, Bertram H, Eberle A, Holleczek B, Schmid-Höpfner S, Waldmann A, et al. Fear of recurrence in long‐term breast cancer survivors—still an issue. Results on prevalence, determinants, and the association with quality of life and depression from the Cancer Survivorship—a multi‐regional population‐based study. Psycho‐Oncology. 2014;23(5):547–54. source
- Supportedcites [54] Costanzo E, Lutgendorf S, Mattes M, Trehan S, Robinson C, Tewfik F, et al. Adjusting to life after treatment: distress and quality of life following treatment for breast cancer. Br J Cancer. 2007;97(12):1625–31. source
The Results section (Univariate models predicting post-treatment distress) reports that younger age predicted greater recurrence worry among women treated for breast cancer (F(1,82)=19.67, P<0.001). This supports the breast-cancer part of the multi-citation sentence; the claim about other cancer types is not attributed to this study alone. (LLM, conf=0.92)
- Partly supportedcites [55] van den Beuken-van Everdingen MH, Peters ML, de Rijke JM, Schouten HC, van Kleef M, Patijn J. Concerns of former breast cancer patients about disease recurrence: a validation and prevalence study. Psycho-Oncology: J Psychol Social Behav Dimensions Cancer. 2008;17(11):1137–45. sourceExperimental — accuracy not yet measured
The Discussion (page not supplied) reports that older former breast cancer patients had lower overall, health, role, and death worries than younger patients. The paper mentions fear of recurrence in other cancer types, but does not report an age association for those cancers. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not checked yet
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This rate is higher than those obtained in previous studies of patients treated for cancer (e.g., breast, lung, pancreatic, endometrial) also using the FCRI-S, which ranged from 53.1 to 60.1% [51].”
§ Fear of cancer recurrence in breast cancer survivors carrying a BRCA1 or 2 genetic mutation : a cross-sectional study > Discussion
What the sources say
- Partly supportedcites [51] Smith AB, Costa D, Galica J, Lebel S, Tauber N, van Helmondt SJ, et al. Spotlight on the fear of cancer recurrence inventory (FCRI). Psychol Res Behav Manage. 2020;13:1257. sourceExperimental — accuracy not yet measured
The Results and Discussion section reports FCRI-SF clinical-FCR rates of 53.9%, 43.3%, and 30%, depending on the cut-off; these are all below the citing study’s 70.8%. It does not report the attributed range of 53.1% to 60.1%, so the precise comparison is not supported by our copy. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
54 more claims · 3 with their cited sources checked
Create a free account to see all 88 claims and to verify the 4 references still open.
- It may state two separate claims as one. 16
- Probably not a substantial claim. 20
Citations
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139 · cited 1×
“The HADS evaluates anxiety and depressive symptoms over the past week [38, 39].”
BackgroundAaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005 · cited 2×
“The complete questionnaire has good psychometric qualities, including a good internal consistency (α ≥ 0.70) and correlations of 0.40 or more between all items and their respective scales [40].”
BackgroundMethodInfluentialDepression and quality of life in older persons: A review
Sivertsen, H., Bjørkløf, G. H., Engedal, K., Selbæk, G., & Helvik, A.-S. (2015) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000437299 · Cited by 14,152
Antoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., Olsson, H., Johannsson, O., Borg, Å., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/375033 · Cited by 3,680 · cited 1×
“This would be particularly true in BRCA1/2 mutation carriers who develop cancer at a younger age as compared to sporadic cancer cases [9], thus possibly increasing their fear of having another cancer at a young age.”
BackgroundRisks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
Kuchenbaecker, K. B., Hopper, J. L., Barnes, D. R., Phillips, K.-A., Mooij, T. M., Roos-Blom, M.-J., Jervis, S., van Leeuwen, F. E., Milne, R. L., Andrieu, N., et al. (2017) · JAMA · doi:10.1001/jama.2017.7112 · Cited by 2,954 · cited 1×
“BRCA1 mutation carriers have an actual greater cancer risk than BRCA2 mutation carriers [33, 56].”
BackgroundValidation of a Decisional Conflict Scale
O'Connor, A. M. (1995) · Medical Decision Making · doi:10.1177/0272989x9501500105 · Cited by 2,452 · cited 2×
“This scale has been validated in the context of various medical and health decision situations and has good psychometric qualities, i.e., a test-retest reliability coefficient of 0.81 over an interval of two weeks and an internal consistency coefficient ranging from 0.78 to 0.92 [48].”
MethodInfluentialAssessing psychological trauma and PTSD
(1997) · Choice Reviews Online · doi:10.5860/choice.34-5966 · Cited by 2,330
Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2
King, M.-C., Marks, J. H., & Mandell, J. B. (2003) · Science · doi:10.1126/science.1088759 · Cited by 2,229
Meta-Analysis of BRCA1 and BRCA2 Penetrance
Chen, S., & Parmigiani, G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.1066 · Cited by 1,802 · cited 1×
“Depending on the study, the lifetime risk of developing breast cancer in BRCA1/2 mutation carriers ranges from 45 to 80% [8–11], which is much higher than in the general population (13”
BackgroundFreeston, M. H., Rhéaume, J., Letarte, H., Dugas, M. J., & Ladouceur, R. (1994) · Personality and Individual Differences · doi:10.1016/0191-8869(94)90048-5 · Cited by 1,731 · cited 1×
“The IUS is used to measure emotional, cognitive, and behavioral reactions to ambiguous situations, the implications of uncertainty, and attempts to control the future [41].”
Background
Research works printed but not linked: 1
- SPSS I. Statistics for Windows (Version 26.0)[Computer Software]. Armonk, NY: IBM Corp; 2019.
Cited by
Savard, J., Filion, C., Brearty, C. M., Caplette‐Gingras, A., Chiquette, J., & Dorval, M. (2024) · Cancer Medicine · doi:10.1002/cam4.6889 · Cited by 11
Self-citationPersonalized Surgery: Innovations, Ethics, and Equity
Cinà, C. S. (2025) · Springer eBooks · doi:10.1007/978-3-032-04866-0_13
Metadata
- Authors
- Michel, A., Dorval, M., Chiquette, J., & Savard, J.
- Affiliations
- Hôpital de l'Enfant-Jésus (CA)
- Corresponding author
- Savard, Josée
- Venue
- Hereditary Cancer in Clinical Practice
- Published
- 2024-08-27
- Volume
- 22
- Issue
- 1
- Pages
- 16-16
- ISSN
- 1731-2302 (ISSN-L)
- 1897-4287
- PMC
- PMC11350945
- OpenAlex
- W4401905534
- Cited by
- 3
- References
- 82
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1
- FWCI
- 0.79
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Hereditary Cancer in Clinical Practice (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- CHU de Québec-Université Laval Foundation (4225)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Women's cancer prevention and management
- Keywords
- fear of cancer recurrence, breast cancer survivors, BRCA1 mutation, BRCA2 mutation, hereditary breast cancer, salpingo-oophorectomy, decisional conflict, regret, avoidance, intolerance of uncertainty, anxiety, depression, quality of life, psychological intervention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fear of cancer recurrence in breast cancer survivors carrying a BRCA1 or 2 genetic mutation : a cross-sectional study. https://app.cochat.ai/papers/10.1186/s13053-024-00285-5
- The paper
- Michel, A., Dorval, M., Chiquette, J., & Savard, J. (2024). Fear of cancer recurrence in breast cancer survivors carrying a BRCA1 or 2 genetic mutation : a cross-sectional study. Hereditary Cancer in Clinical Practice. https://doi.org/10.1186/s13053-024-00285-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.